464 related articles for article (PubMed ID: 24674779)
21. Anti-aquaporin-4 antibodies in neuromyelitis optica: how to prove their pathogenetic relevance?
Bradl M; Lassmann DH
Int MS J; 2008 Sep; 15(3):75-8. PubMed ID: 18812056
[TBL] [Abstract][Full Text] [Related]
22. Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells.
Hinson SR; McKeon A; Fryer JP; Apiwattanakul M; Lennon VA; Pittock SJ
Arch Neurol; 2009 Sep; 66(9):1164-7. PubMed ID: 19752309
[TBL] [Abstract][Full Text] [Related]
23. Clinical evaluation of rituximab treatment for neuromyelitis optica.
Fernández-Megía MJ; Casanova-Estruch B; Pérez-Miralles F; Ruiz-Ramos J; Alcalá-Vicente C; Poveda-Andrés JL
Neurologia; 2015 Oct; 30(8):461-4. PubMed ID: 25444411
[TBL] [Abstract][Full Text] [Related]
24. Epidemiological, clinical, and immunological characteristics of neuromyelitis optica: A review.
Pereira WL; Reiche EM; Kallaur AP; Kaimen-Maciel DR
J Neurol Sci; 2015 Aug; 355(1-2):7-17. PubMed ID: 26050520
[TBL] [Abstract][Full Text] [Related]
25. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo.
Bradl M; Misu T; Takahashi T; Watanabe M; Mader S; Reindl M; Adzemovic M; Bauer J; Berger T; Fujihara K; Itoyama Y; Lassmann H
Ann Neurol; 2009 Nov; 66(5):630-43. PubMed ID: 19937948
[TBL] [Abstract][Full Text] [Related]
26. [Neuromyelitis optica and anti-aquaporin 4 antibody--an overview].
Misu T; Fujihara K; Itoyama Y
Brain Nerve; 2008 May; 60(5):527-37. PubMed ID: 18516975
[TBL] [Abstract][Full Text] [Related]
27. Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica.
Jarius S; Paul F; Franciotta D; Waters P; Zipp F; Hohlfeld R; Vincent A; Wildemann B
Nat Clin Pract Neurol; 2008 Apr; 4(4):202-14. PubMed ID: 18334978
[TBL] [Abstract][Full Text] [Related]
28. Immunology of neuromyelitis optica: a T cell-B cell collaboration.
Mitsdoerffer M; Kuchroo V; Korn T
Ann N Y Acad Sci; 2013 Apr; 1283():57-66. PubMed ID: 23617588
[TBL] [Abstract][Full Text] [Related]
29. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis.
Roemer SF; Parisi JE; Lennon VA; Benarroch EE; Lassmann H; Bruck W; Mandler RN; Weinshenker BG; Pittock SJ; Wingerchuk DM; Lucchinetti CF
Brain; 2007 May; 130(Pt 5):1194-205. PubMed ID: 17282996
[TBL] [Abstract][Full Text] [Related]
30. Neuromyelitis optica (NMO) antibody positivity in patients with transverse myelitis and no visual manifestations.
Hamnik SE; Hacein-Bey L; Biller J; Gruener G; Jay W
Semin Ophthalmol; 2008; 23(3):191-200. PubMed ID: 18432545
[TBL] [Abstract][Full Text] [Related]
31. [Treatment of neuromyelitis optica].
Fujihara K
Nihon Rinsho Meneki Gakkai Kaishi; 2012; 35(2):129-35. PubMed ID: 22576570
[TBL] [Abstract][Full Text] [Related]
32. Effector functions of antiaquaporin-4 autoantibodies in neuromyelitis optica.
Cayrol R; Saikali P; Vincent T
Ann N Y Acad Sci; 2009 Sep; 1173():478-86. PubMed ID: 19758189
[TBL] [Abstract][Full Text] [Related]
33. Rituximab-induced interstitial lung disease in a patient with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder.
Ahn SH; Kim SM; Sung JJ
Mult Scler Relat Disord; 2018 Feb; 20():192-193. PubMed ID: 29414297
[TBL] [Abstract][Full Text] [Related]
34. Neuromyelitis optica and pregnancy during therapeutic B cell depletion: infant exposure to anti-AQP4 antibody and prevention of rebound relapses with low-dose rituximab postpartum.
Ringelstein M; Harmel J; Distelmaier F; Ingwersen J; Menge T; Hellwig K; Kieseier B; Mayatepek E; Hartung HP; Kuempfel T; Aktas O
Mult Scler; 2013 Oct; 19(11):1544-7. PubMed ID: 23886825
[TBL] [Abstract][Full Text] [Related]
35. Neuromyelitis Optica (Devic's Syndrome): an Appraisal.
Crout TM; Parks LP; Majithia V
Curr Rheumatol Rep; 2016 Aug; 18(8):54. PubMed ID: 27402111
[TBL] [Abstract][Full Text] [Related]
36. [Neuromyelitis optica in children. Two case reports].
Tosello B; Halbert C; Mancini J; Chabrol B; Boucraut J; Milh M
Arch Pediatr; 2012 Aug; 19(8):827-31. PubMed ID: 22789744
[TBL] [Abstract][Full Text] [Related]
37. Neuromyelitis optica-IgG in idiopathic inflammatory demyelinating disorders amongst Hong Kong Chinese.
Chan KH; Ramsden DB; Yu YL; Kwok KH; Chu AC; Ho PW; Kwan JS; Lee R; Lim E; Kung MH; Ho SL
Eur J Neurol; 2009 Mar; 16(3):310-6. PubMed ID: 19138340
[TBL] [Abstract][Full Text] [Related]
38. [Humoral and cellular immune responses in neuromyelitis optica].
Kawachi I
Rinsho Shinkeigaku; 2010 Nov; 50(11):873-4. PubMed ID: 21921483
[TBL] [Abstract][Full Text] [Related]
39. Anti-aquaporin-4 auto-antibodies orchestrate the pathogenesis in neuromyelitis optica.
Saikali P; Cayrol R; Vincent T
Autoimmun Rev; 2009 Dec; 9(2):132-5. PubMed ID: 19389490
[TBL] [Abstract][Full Text] [Related]
40. The IL-10-producing regulatory B cells (B10 cells) and regulatory T cell subsets in neuromyelitis optica spectrum disorder.
Cho EB; Cho HJ; Seok JM; Min JH; Kang ES; Kim BJ
Neurol Sci; 2018 Mar; 39(3):543-549. PubMed ID: 29349658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
